05/26/2011
Tesfaldet T. Michael, MD, MPH; Donald Haagen, RCIS, MD; Tayo Addo, MD; Aristotelis C. Papayannis, MD; Abdul-Rahman Abdel-Karim, MD; Bilal Saeed, MD; Panagiotis Karyofillis, MD; Biswajit Kar, MD; Peter B. Berger, MD; Christopher Lichtenwalter, MD; Emmanouil S. Brilakis, MD, PhD, FACC, FAHA, FESC, FSCAI; Owen Obel, MD; Subhash Banerjee, MD, FSCAI; Joseph K. Bissett, MD; Rajesh Sachdeva, MD; Vassilios V. Voudris, MD, PhD; Michele Roesle, RN, BSN, MD; James Rossen, MD; Bavana V. Rangan, BDS, MPH, MD; Panayotis Fasseas, MD; James A. de Lemos, MD
ABSTRACT: The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions,...
ABSTRACT: The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions,...
ABSTRACT: The Stenting of...